Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001493152-24-000295
Filing Date
2024-01-03
Accepted
2024-01-03 16:18:58
Documents
16
Period of Report
2023-10-18
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-ka.htm   iXBRL 8-K/A 42043
2 ex23-1.htm EX-23.1 4486
3 ex99-1.htm EX-99.1 680125
4 ex99-2.htm EX-99.2 193463
5 ex99-3.htm EX-99.3 139683
  Complete submission text file 0001493152-24-000295.txt   1319165

Data Files

Seq Description Document Type Size
6 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT adxs-20231018.xsd EX-101.SCH 3024
7 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT adxs-20231018_lab.xml EX-101.LAB 34240
8 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT adxs-20231018_pre.xml EX-101.PRE 22365
10 EXTRACTED XBRL INSTANCE DOCUMENT form8-ka_htm.xml XML 3193
Mailing Address 9 DEER PARK DRIVE SUITE K-1 MONMOUTH JUNCTION NJ 08852
Business Address 9 DEER PARK DRIVE SUITE K-1 MONMOUTH JUNCTION NJ 08852 732 545 1590
Ayala Pharmaceuticals, Inc. (Filer) CIK: 0001100397 (see all company filings)

EIN.: 841521955 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-36138 | Film No.: 24506690
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)